



Invest like a pro, with the pros.



---

[www.capitalideasmedia.com](http://www.capitalideasmedia.com)

---

## Morning Need to Know

Getting you ready for your investing day

September 14, 2020

Written & curated by Sean Mason, Associate  
Publisher, Capital Ideas Media



### CANADIAN ANALYSTS' CALLS

---

**Silvercorp Metals Inc. (TSX:SVM).** Canaccord Genuity analyst Dalton Baretto initiated coverage of the silver miner with a \$12 per share target price, believing the stock is “compelling” for investors seeking leverage to the price of silver.

“SVM offers the highest revenue exposure to silver among the mid-cap precious metals producers we cover. We estimate SVM will generate two-thirds of its revenue from silver. In our view, this exposure, coupled with the recent rise in investor interest in silver leverage, could provide SVM with a ‘scarcity

premium' in its trading multiples. We believe this is already occurring: SVM currently trades at 12.4 times our 2021 EBITDA estimate and 1.7 times NAV, vs. the mid-cap precious metals peer group averages of 5.3 times and 1.1 times, respectively," he said.

### **WELL Health Technologies Corp. (TSX:WELL)**

Desjardins Securities analyst David Newman increased his target price on the stock to \$7 per share from \$5, while maintaining a "Buy" rating, raising his financial expectations for WELL at further examination of its US\$14-million acquisition of California-based telehealth company Circle Medical.

"We have increased our estimates and target price, reflective of Circle's: (1) robust omni-channel offering, including its digital portfolio (telehealth witnessing explosive growth); (2) affordable per-use virtual care offerings, with high net promoter scores, backstopped by major payers; and (3) significant U.S. expansion opportunity (to 50 U.S. states, planned clinic and digital M&A)," the analyst wrote.



## **U.S. ANALYSTS' CALLS**

---

**McDonald's (NYSE:MCD).** UBS raised its price target on shares of the fast food giant from \$215 to \$230.

**GameStop Corp. (NYSE:GME).** Jefferies upgraded shares of the video game accessories maker to "Buy" with an \$8 per share target price.



## STOCKS THAT MAY MOVE

---

**Trillium Therapeutics Inc. (TSX:TRIL)** will be added to the S&P/TSX Composite Index before the open of trading on Monday, September 21, 2020, S&P Dow Jones Indices announced.

**ATS Automation Tooling Systems Inc. (TSX:ATA)** said it has received a \$20 million order booking from a medical device manufacturer to produce a COVID-19 vaccine syringe manufacturing line.

**Americas Gold and Silver Corporation (TSX:USA)** reported that the measured and indicated silver

resource at its 60% owned Galena Complex in Idaho increased from 27.4 million ounces to 37.3 million ounces, and the Inferred silver resource increased from 39.0 million ounces to 78.6 million ounces.

## **MARKETS**

---

**S&P/TSX and U.S. equity futures** are pointing to a sharply higher open Monday on optimism for a COVID-19 vaccine by year end.

---

## **CURRENCIES**

---

**The Canadian dollar** is up 0.02 at 0.7591 (U.S.).

---

## **COMMODITIES**

---

**West Texas Intermediate crude oil** fell 0.9% at \$37.01 on worries over renewed Libyan supply.

**Gold** gained 0.6% to \$1,959.50 an ounce.

---

Please email questions, comments or concerns to:

[\*customercare@capitalideasresearch.com\*](mailto:customercare@capitalideasresearch.com)

---

Access, insight and ideas.

Sean Mason  
Associate Publisher,  
Capital Ideas Media

[www.capitalideamedia.com](http://www.capitalideamedia.com)



---

The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from

outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

*Copyright © 2016 Capital Ideas Research, All rights reserved.*

You are receiving this email because you are part of our investment network.

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5G 3P4 · Canada